Artificial intelligence (AI) is revolutionizing healthcare, enhancing efficiency and accuracy in daily operations, particularly in clinical trial prescreening. The 340B Drug Pricing Program, created in 1992, aims to provide eligible healthcare organizations access to outpatient drugs at reduced prices, allowing them to maximize resources and improve patient care. Incorporating AI tools, like the RECTIFIER system, can significantly improve 340B program management. These AI solutions effectively analyze unstructured data from electronic health records (EHRs), streamlining eligibility assessments and reducing time for prescreening tasks. For instance, AI achieved a 20.4% eligibility rate in heart failure trials, outperforming manual reviews. By automating data analysis and identifying eligibility, AI can enhance 340B operations, minimize compliance errors, and optimize resource allocation. Ultimately, AI serves as a vital support tool, empowering healthcare professionals to focus on critical tasks while ensuring program integrity and better patient outcomes.
Source link
Share
Read more